340B Contract Pharmacy Revenue and Pharmacy Valuation
For many independent pharmacies, serving as a 340B contract pharmacy for a hospital or clinic has become a meaningful source of revenue. When that pharmacy is sold, refinanced or brought into a partnership, a hard question follows: how much of that revenue should count toward value, and how much should a lender rely on it?
This article explains why buyers and lenders often treat contract pharmacy revenue differently from core dispensing income and what owners can do to document it. Program rules, contract terms and manufacturer policies change and are the subject of ongoing disputes, and nothing here is legal, regulatory, billing or compliance advice. Owners should rely on healthcare counsel and qualified compliance professionals.
How 340B Contract Pharmacy Arrangements Work
Under the federal drug pricing program, eligible hospitals and clinics, often called covered entities, may purchase certain outpatient drugs at reduced prices. Some covered entities contract with outside pharmacies to dispense those drugs to their eligible patients. The contract pharmacy typically receives a dispensing fee or other compensation under its agreement, while a third-party administrator may help manage claims and inventory replenishment.
The economics vary widely by agreement. Some pharmacies earn modest fees, while others see significant revenue tied to one or a few covered entities. Owners do not always track this income separately, which can make it hard for an outside reader to see how much of the pharmacy’s profit depends on it.
Why 340B Contract Pharmacy Revenue Is Viewed as Volatile
Buyers and lenders tend to see this revenue as less durable than traditional dispensing income for several reasons.
- Contract concentration: revenue may depend on one covered entity that can end or change the agreement
- Termination rights: many agreements allow termination with notice, sometimes without cause
- Manufacturer restrictions: some manufacturers have limited distribution to contract pharmacies, reducing eligible volume
- Policy and legal change: legislation, litigation and state laws continue to shape how contract pharmacy arrangements work
- Compliance exposure: errors such as duplicate discounts or diversion can lead to repayment obligations for the covered entity and disputes with the pharmacy
- Assignment limits: agreements may not transfer to a buyer without the covered entity’s consent
Because of these factors, contract revenue should not be assumed to continue after a sale.
How Buyers and Lenders May Treat This Revenue
When valuing a pharmacy or underwriting a loan, buyers and lenders may take different approaches:
- Exclude contract pharmacy income entirely and value the business on core operations
- Include it only to the extent supported by a long contract history and stable trends
- Apply a discount to reflect concentration and policy risk
- Tie part of the purchase price to the continuation of the agreement after closing
If part of the price depends on future contract revenue, lenders and program rules may limit earnouts, and seller notes are typically subordinate to the primary lender. Our article on pharmacy acquisition earnouts explains these structures.
For background on how valuation works in general, see how a pharmacy practice is valued.
The Effect on Cash Flow Underwriting
Lenders generally base loan size on cash flow that can reasonably be expected to continue. If a meaningful share of cash flow comes from one 340B contract pharmacy agreement, a lender may stress test the deal by asking whether the pharmacy could still cover its debt payments if that revenue declined or ended. Our article on how pharmacy lenders evaluate cash flow explains that analysis.
The same logic applies to other volatile revenue and fees. Our article on how DIR fees affect pharmacy valuation covers a related issue on the cost side.
How Sellers Can Document Contract Revenue
Owners who expect contract revenue to support value should prepare clear documentation well before a sale or loan request.
- Every contract pharmacy agreement, including amendments and termination provisions
- Monthly revenue and claim volume by covered entity over several years
- Separate tracking of contract revenue and core dispensing revenue
- Any audit history, findings and corrective actions, reviewed by qualified compliance professionals
- Correspondence about changes in manufacturer participation
- Whether the covered entity has indicated it will consent to an assignment
Separating this revenue clearly in the financial statements can make it easier for buyers and lenders to understand the core business on its own.
Due Diligence for Buyers
Buyers evaluating a pharmacy with contract revenue should add several items to a standard pharmacy due diligence checklist:
- Confirm the remaining term and termination rights of each agreement
- Ask counsel whether the agreement can be assigned and what consent is required
- Review trends in eligible volume over recent periods
- Speak with the covered entity, if permitted, about its plans
- Model the pharmacy’s cash flow with and without the contract revenue
Planning a Sale With Contract Revenue
Sellers who rely heavily on contract revenue may benefit from planning well ahead. Building core dispensing and clinical revenue, extending agreement terms where possible and documenting performance can improve how buyers view the business. Advisors experienced in pharmacy transactions can help set realistic expectations. Our advisory and consulting services support owners preparing for a sale or valuation.
Final Thoughts
Revenue from serving as a 340B contract pharmacy can be valuable, but buyers and lenders are likely to treat it with caution because it is concentrated, contract-dependent and subject to ongoing policy change. Owners who document it carefully and strengthen their core business can present a more credible picture of value.
US Medical Funding helps pharmacists finance acquisitions and evaluate how different revenue sources affect a deal. Learn more about our pharmacy acquisition financing.



